A Comparative overview of Older Vs Newer Antiepileptic Medications (AEDs)

Clicks: 1
ID: 309147
2025
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #96 of 153 articles by views in International Journal of Pharmaceutical Drug Design (IJPDD)

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 153 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
For many years, antiepileptic medications (AEDs) have been the mainstay of epilepsy treatment. Although they are well-established in clinical practice, older AEDs like phenytoin, carbamazepine, and valproate have a number of limitations. These include complex pharmacokinetic interactions brought on by enzyme stimulation, a greater risk of teratogenicity, bone loss, and neuropsychiatric adverse effects. On the other hand, more recent AEDs with better safety profiles include levetiracetam, lamotrigine, oxcarbazepine, and lacosamide. They are less likely to cause drug-drug interactions, have fewer negative effects on cognition and psychiatry, and are typically better tolerated. These benefits make them especially appropriate for older people and those who need polypharmacy due to comorbidities. Newer AEDs frequently have higher prices and less long-term safety evidence, despite these advantages. For example, levetiracetam is an effective medication, but dosing tactics might affect its acceptability; slower titration and lower doses reduce adverse effects.
Reference Key
imported_1761926384_6904dcf050072 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Divya Juyal
Journal International Journal of Pharmaceutical Drug Design (IJPDD)
Year 2025
DOI
10.62896/ijpdd.2.6.06
URL
https://ijpdd.org/index.php/files/article/view/296
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.